Literature DB >> 35228747

Bystander T cells in cancer immunology and therapy.

Stefanie L Meier1,2, Ansuman T Satpathy1,2, Daniel K Wells3.   

Abstract

Cancer-specific T cells are required for effective anti-cancer immunity and have a central role in cancer immunotherapy. However, emerging evidence suggests that only a small fraction of tumor-infiltrating T cells are cancer specific, and T cells that recognize cancer-unrelated antigens (so-called 'bystanders') are abundant. Although the role of cancer-specific T cells in anti-cancer immunity has been well established, the implications of bystander T cells in tumors are only beginning to be understood. It is becoming increasingly clear that bystander T cells are not a homogeneous group of cells but, instead, they differ in their specificities, their activation states and effector functions. In this Perspective, we discuss recent studies of bystander T cells in tumors, including experimental and computational approaches that enable their identification and functional analysis and viewpoints on how these insights could be used to develop new therapeutic approaches for cancer immunotherapy.
© 2022. Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35228747     DOI: 10.1038/s43018-022-00335-8

Source DB:  PubMed          Journal:  Nat Cancer        ISSN: 2662-1347


  108 in total

Review 1.  'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.

Authors:  Eric Tran; Paul F Robbins; Steven A Rosenberg
Journal:  Nat Immunol       Date:  2017-02-15       Impact factor: 25.606

2.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

3.  The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.

Authors:  Volker Lennerz; Martina Fatho; Chiara Gentilini; Roy A Frye; Alexander Lifke; Dorothea Ferel; Catherine Wölfel; Christoph Huber; Thomas Wölfel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-24       Impact factor: 11.205

Review 4.  Adoptive cell transfer as personalized immunotherapy for human cancer.

Authors:  Steven A Rosenberg; Nicholas P Restifo
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

5.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Authors:  Robert M Samstein; Chung-Han Lee; Alexander N Shoushtari; Matthew D Hellmann; Ronglai Shen; Yelena Y Janjigian; David A Barron; Ahmet Zehir; Emmet J Jordan; Antonio Omuro; Thomas J Kaley; Sviatoslav M Kendall; Robert J Motzer; A Ari Hakimi; Martin H Voss; Paul Russo; Jonathan Rosenberg; Gopa Iyer; Bernard H Bochner; Dean F Bajorin; Hikmat A Al-Ahmadie; Jamie E Chaft; Charles M Rudin; Gregory J Riely; Shrujal Baxi; Alan L Ho; Richard J Wong; David G Pfister; Jedd D Wolchok; Christopher A Barker; Philip H Gutin; Cameron W Brennan; Viviane Tabar; Ingo K Mellinghoff; Lisa M DeAngelis; Charlotte E Ariyan; Nancy Lee; William D Tap; Mrinal M Gounder; Sandra P D'Angelo; Leonard Saltz; Zsofia K Stadler; Howard I Scher; Jose Baselga; Pedram Razavi; Christopher A Klebanoff; Rona Yaeger; Neil H Segal; Geoffrey Y Ku; Ronald P DeMatteo; Marc Ladanyi; Naiyer A Rizvi; Michael F Berger; Nadeem Riaz; David B Solit; Timothy A Chan; Luc G T Morris
Journal:  Nat Genet       Date:  2019-01-14       Impact factor: 38.330

6.  Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.

Authors:  Yannick Simoni; Etienne Becht; Michael Fehlings; Chiew Yee Loh; Si-Lin Koo; Karen Wei Weng Teng; Joe Poh Sheng Yeong; Rahul Nahar; Tong Zhang; Hassen Kared; Kaibo Duan; Nicholas Ang; Michael Poidinger; Yin Yeng Lee; Anis Larbi; Alexis J Khng; Emile Tan; Cherylin Fu; Ronnie Mathew; Melissa Teo; Wan Teck Lim; Chee Keong Toh; Boon-Hean Ong; Tina Koh; Axel M Hillmer; Angela Takano; Tony Kiat Hon Lim; Eng Huat Tan; Weiwei Zhai; Daniel S W Tan; Iain Beehuat Tan; Evan W Newell
Journal:  Nature       Date:  2018-05-16       Impact factor: 49.962

Review 7.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

Review 8.  Turning the corner on therapeutic cancer vaccines.

Authors:  Robert E Hollingsworth; Kathrin Jansen
Journal:  NPJ Vaccines       Date:  2019-02-08       Impact factor: 7.344

9.  Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy.

Authors:  Pamela C Rosato; Sathi Wijeyesinghe; J Michael Stolley; Christine E Nelson; Rachel L Davis; Luke S Manlove; Christopher A Pennell; Bruce R Blazar; Clark C Chen; Melissa A Geller; Vaiva Vezys; David Masopust
Journal:  Nat Commun       Date:  2019-02-04       Impact factor: 14.919

10.  Comprehensive T cell repertoire characterization of non-small cell lung cancer.

Authors:  Alexandre Reuben; Jiexin Zhang; Shin-Heng Chiou; Rachel M Gittelman; Jun Li; Won-Chul Lee; Junya Fujimoto; Carmen Behrens; Xiaoke Liu; Feng Wang; Kelly Quek; Chunlin Wang; Farrah Kheradmand; Runzhe Chen; Chi-Wan Chow; Heather Lin; Chantale Bernatchez; Ali Jalali; Xin Hu; Chang-Jiun Wu; Agda Karina Eterovic; Edwin Roger Parra; Erik Yusko; Ryan Emerson; Sharon Benzeno; Marissa Vignali; Xifeng Wu; Yuanqing Ye; Latasha D Little; Curtis Gumbs; Xizeng Mao; Xingzhi Song; Samantha Tippen; Rebecca L Thornton; Tina Cascone; Alexandra Snyder; Jennifer A Wargo; Roy Herbst; Stephen Swisher; Humam Kadara; Cesar Moran; Neda Kalhor; Jianhua Zhang; Paul Scheet; Ara A Vaporciyan; Boris Sepesi; Don L Gibbons; Harlan Robins; Patrick Hwu; John V Heymach; Padmanee Sharma; James P Allison; Veera Baladandayuthapani; Jack J Lee; Mark M Davis; Ignacio I Wistuba; P Andrew Futreal; Jianjun Zhang
Journal:  Nat Commun       Date:  2020-01-30       Impact factor: 14.919

View more
  6 in total

Review 1.  Clinical implications of T cell exhaustion for cancer immunotherapy.

Authors:  Andrew Chow; Karlo Perica; Christopher A Klebanoff; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2022-10-10       Impact factor: 65.011

2.  Cancer Immunoediting in the Era of Immuno-oncology.

Authors:  Matthew M Gubin; Matthew D Vesely
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

3.  Transcriptional and genetic alterations of cuproptosis-related genes correlated to malignancy and immune-infiltrate of esophageal carcinoma.

Authors:  Runmin Jiang; Yu Huan; Yan Li; Xinyue Gao; Qiang Sun; Feng Zhang; Tao Jiang
Journal:  Cell Death Discov       Date:  2022-08-22

Review 4.  Phenotypic, functional, and metabolic heterogeneity of immune cells infiltrating non-small cell lung cancer.

Authors:  Beatrice Aramini; Valentina Masciale; Anna Valeria Samarelli; Alessandra Dubini; Michele Gaudio; Franco Stella; Uliano Morandi; Massimo Dominici; Sara De Biasi; Lara Gibellini; Andrea Cossarizza
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

Review 5.  Neutrophils: Musketeers against immunotherapy.

Authors:  Kashif Rafiq Zahid; Umar Raza; Soumya Tumbath; Lingxiang Jiang; Wenjuan Xu; Xiumei Huang
Journal:  Front Oncol       Date:  2022-08-25       Impact factor: 5.738

Review 6.  Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer.

Authors:  Davide Massa; Anna Tosi; Antonio Rosato; Valentina Guarneri; Maria Vittoria Dieci
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.